Table 2. Pharmacokinetic Study Design for FTY720-C2 and FTY720-Mitoxy.
| Test article | Route of Administration | Na | Dose Level (mg/kg) | Dose Conc. (mg/mL) | Dose Volume (mL/kg) | Blood Collection and Necropsyb Time Points (Postdose) |
|---|---|---|---|---|---|---|
| FTY720-C2 | Oral | 8 | 1 | 0.2 | 5 | 1, 8, 24, and 48 hr |
| FTY720-Mitoxy | Oral | 8 | 2 | 0.4 | 5 | 1, 8, 24, and 48 hr |
| FTY720-C2 | Intravenous | 8 | 1 | 0.5 | 2 | 5 min, 8, 24, and 48 hr |
| FTY720-Mitoxy | Intravenous | 8 | 2 | 1 | 2 | 5 min, 8, 24, and 48 hr |
aTwo animals per time point (n = 2).
bMouse brain and adrenal glands were collected upon necropsy for pharmacokinetic study and protein phosphatase assay, respectively.